On the other hand, tumor cells express suppressive molecules (such as indoleamine 2,3-dioxygenase (IDO), adenosine, and CCL2) to inhibit T-cell activity and recruit Tregs to tumor sites, impairing immunotherapy efficacy [21–23]. This evidence concerns the gene CCL2 and neoplasm.